title: Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
authors.affiliation: Endocrinology Department, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre.
authors.forename: G H
authors.initials: GH
authors.lastname: Teló
authors.affiliation: School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90619-900, Brazil.
authors.forename: G F
authors.initials: GF
authors.lastname: Carvalhal
authors.affiliation: School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90619-900, Brazil.
authors.forename: C G S
authors.initials: CGS
authors.lastname: Cauduro
authors.affiliation: Clinical Research Center, PUCRS, Porto Alegre, Brazil.
authors.forename: V S
authors.initials: VS
authors.lastname: Webber
authors.affiliation: School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90619-900, Brazil.|Clinical Research Center, PUCRS, Porto Alegre, Brazil.|Medical Oncology, Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil.|Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
authors.forename: C H
authors.initials: CH
authors.lastname: Barrios
authors.affiliation: School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90619-900, Brazil.|Clinical Research Center, PUCRS, Porto Alegre, Brazil.|Medical Oncology, Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil.|Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
authors.forename: A P
authors.initials: AP
authors.lastname: Fay
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000276:immunology; D006801:Humans; D000074324:Ipilimumab / Q000008:administration & dosage / Q000276:immunology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D000077594:Nivolumab